Cargando…

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile

Mast cells (MCs) represent a population of hematopoietic cells with a key role in innate and adaptive immunity and are well known for their detrimental role in allergic responses. Yet, MCs occur in low abundance, which hampers their detailed molecular analysis. Here, we capitalized on the potential...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Toledo, Marcelo A. S., Fu, Xuhuang, Maié, Tiago, Buhl, Eva M., Götz, Katrin, Schmitz, Susanne, Kaiser, Anne, Boor, Peter, Braunschweig, Till, Chatain, Nicolas, Costa, Ivan G., Brümmendorf, Tim H., Koschmieder, Steffen, Zenke, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049485/ https://www.ncbi.nlm.nih.gov/pubmed/36982353 http://dx.doi.org/10.3390/ijms24065275

Ejemplares similares

Towards personalized medicine with iPS cell technology: a case report of advanced systemic mastocytosis with associated eosinophilia
por: Atakhanov, Salim, et al.
Publicado: (2022)

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
por: Zappulla, Jacques P., et al.
Publicado: (2005)

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis
por: Lyberg, Katarina, et al.
Publicado: (2016)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

De novo Leukemic Variant of Mast Cell Leukemia With KIT D816V
por: Bang, Hae In, et al.
Publicado: (2015)

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
por: Grootens, Jennine, et al.
Publicado: (2019)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021)

Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report
por: Cao, Lihong, et al.
Publicado: (2023)

A new humanized in vivo model of KIT D816V(+) advanced systemic mastocytosis monitored using a secreted luciferase
por: Bibi, Siham, et al.
Publicado: (2016)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production
por: Tobío, Araceli, et al.
Publicado: (2020)

P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Kaiser, Anne, et al.
Publicado: (2023)

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
por: Parting, Oliver, et al.
Publicado: (2020)

Human DC3 Antigen Presenting Dendritic Cells From Induced Pluripotent Stem Cells
por: Satoh, Taiki, et al.
Publicado: (2021)

CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis
por: Bandara, Geethani, et al.
Publicado: (2023)

Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT
por: Bandara, Geethani, et al.
Publicado: (2018)

KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia
por: Lopes, Marta, et al.
Publicado: (2018)

Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation
por: Suh, Myung Chul, et al.
Publicado: (2017)

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2017)

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report
por: Malik, Faizan, et al.
Publicado: (2017)

The spleen microenvironment influences disease transformation in a mouse model of KIT(D816V)-dependent myeloproliferative neoplasm
por: Pelusi, Natalie, et al.
Publicado: (2017)

Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis
por: KWIATKOWSKA, Dominika, et al.
Publicado: (2021)

Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation
por: Möller Westerberg, C, et al.
Publicado: (2012)

Mastocytosis and Mast Cell Activation Disorders: Clearing the Air
por: Jackson, Clayton Webster, et al.
Publicado: (2021)

CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes
por: Olschok, Kathrin, et al.
Publicado: (2021)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
por: Schubert, Claudia, et al.
Publicado: (2019)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Presumed mast cell choroidal infiltrate in aggressive systemic mastocytosis
por: Tran, Tu M., et al.
Publicado: (2020)

Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis
por: Reszka, Edyta, et al.
Publicado: (2021)

A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis
por: Gülen, Theo
Publicado: (2023)

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder
por: Chatterjee, Anindya, et al.
Publicado: (2015)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells
por: Baumeister, Julian, et al.
Publicado: (2021)

COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
por: Giannetti, Matthew P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kkn0t7pemik16d9o24db6rie7t